Live
FierceBiotechSummit's PD-1xVEGF interim trial miss surprises analysts, shares tumbleEndpoints NewsAcelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from ChinaEndpoints NewsSave the date: Premium subscriber-exclusive Post-Hoc LiveEndpoints NewsFDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B dealBioWorldDermatology specialist Leo Pharma makes a $50M move into gene therapyBioPharma DiveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookFierceBiotechCBER chief Prasad steps aside, deputy takes the reins as search for successor continuesFierceBiotechJ&J axes $5B CAR-T dream months after touting best-in-disease efficacyEndpoints NewsSummit slips on ivonescimab's apparent interim miss in sign of investor frustrationEndpoints NewsAmgen files update to Tavneos label as FDA escalates push to withdrawFierceBiotechChutes & Ladders—Astellas appoints new top strategist from Sanofi JapanFierceBiotechLigand tries to disembark from part of Viking pact, alleging contract breach
eLife 1 mai 2026

RadD from <i>Fusobacterium nucleatum</i> engages NKp46 to promote antitumor cytotoxicity

RadD from Fusobacterium nucleatum engages NKp46 to promote antitumor cytotoxicity

Original
Contenu indisponible. Consultez la source originale.